Bolt Biotherapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 57.9% | 57.9% | -130.5% |
| FY2021 | -39.4% | -39.4% | -32.0% |
| FY2022 | -51.4% | -51.4% | -38.7% |
| FY2023 | -61.4% | -61.4% | -43.3% |
| FY2024 | -110.4% | -110.4% | -63.4% |
| FY2025 | -125.9% | -125.9% | -58.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | 57.9% | 57.9% | -130.5% |
| FY2021 | -39.4% | -39.4% | -32.0% |
| FY2022 | -51.4% | -51.4% | -38.7% |
| FY2023 | -61.4% | -61.4% | -43.3% |
| FY2024 | -110.4% | -110.4% | -63.4% |
| FY2025 | -125.9% | -125.9% | -58.8% |